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Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be
combined to increase efficacy.Objective.We usedMTX, RTX, andmethylprednisolone in a single combined regiment and observed
patients prospectively.Methods.We present results of observational pilot study of combined therapy of RTX andMTX in 28 patients
with active MS. Therapeutic protocol consisted of two infusions within 14 days. First infusion was 1000mg methylprednisolone
(MP) IV, 1000mg RTX IV, and 20mgMTX IV. On day 14, 1000mgMP IV and 1000mg RTX IV were given. Patients were followed
prospectively from 12 to 48 months. Results and Conclusion. There were no relapses among all 28 patients during the observation
period. B-cell depletion of CD19+ and CD19+/CD27+ memory B-cell subpopulation in both compartments was confirmed in all
patients at 6 months. We found a more rapid reconstitution of B cells in the CSF than in the peripheral blood and longstanding
depression of CD19+CD27+ memory B-cell. Conclusion. Effectiveness of combined regimen of RTX and MTX could be related to
longstanding depletion of CD19+CD27+ memory B-cell subset.
1. Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory
disease of the CNS, characterized by focal demyelination, loss
of axons, and gliosis that result in neurological symptoms.
While our understanding ofMS immunopathology continues
to improve, the underlying etiology of the disorder remains
unclear.
The overall efficacy of traditional MS treatments (beta-
interferon, glatiramer acetate) is limited, and these drugs
are widely accepted to have a relatively small effect on
disease activity [1, 2]. More powerful approaches to disease
modification in MS include the so-called “biological thera-
pies” or monoclonal antibodies (natalizumab, alemtuzumab,
daclizumab, rituximab, andocrelizumab) and cytotoxic drugs
(cladribine and mitoxantrone) [3–6]. The use of these ther-
apies is limited by concerns regarding potential side effects,
including an increased risk of infection and a theoretical
increase in the lifetime risk of malignancy. It is thought that
at least some of these risks increase as the cumulative dose of
the drug increases [7].
Clinical trials of the anti-CD20 monoclonal antibody
rituximab (RTX) in rheumatoid arthritis, systemic con-
nective tissue diseases, and ANCA-associated vasculitides
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have reinforced its position as one of the leading potential
therapeutic options in a range of autoimmune diseases [3, 8–
11]. InMS, CD20+ B cells are rapidly becoming recognized as
a valid therapeutic target, partly due to an increasing interest
in their role in MS pathogenesis. The role of B cells in MS
appears to be wide ranging and pervasive and includes the
production of autoantibodies, antigen presentation to T cells,
proinflammatory cytokine release, and tertiary lymphoid
tissue formation in CNS of MS patients [12].
Studies examining the efficacy of RTX as a therapy in
MS are limited. The largest and most important study to
date is Helping to Evaluate Rituxan (rituximab) in Relapsing-
Remitting Multiple Sclerosis (HERMES). Results demon-
strated the ability of RTX to substantially control the focal
inflammatory process in MS based on both MRI and clinical
data. However, RTX did not completely suppress relapses—
10 patients (14.5% of patients) experienced a clinical relapse
during the first 24 weeks of the study [13]. Besides the
inability of RTX to cross the blood-brain barrier, the limited
efficacy of RTX monotherapy could also be explained by the
capability of B cells to survive in certain tissues—referred
to as “privileged sites.” This phenomenon has been seen
in rheumatoid arthritis; pathological B cells found in the
synovial lining of joints were decreased in number but not
eliminated by RTX treatment [14, 15].
Mitoxantrone (MTX) is a topoisomerase II inhibitor that
is commonly used in the treatment of MS. Its clinical efficacy
has been proven in a number of controlled studies [16, 17].
In animal models of MS, MTX was found to be tenfold
more potent when compared to cyclophosphamide [18]. The
effect of MTX may be partly due to its ability to induce B-
cell apoptosis. It appears that the subpopulation that is most
sensitive to this effect is the CD19+/CD27+ memory B cells.
Additional clinical studies have shown correlations between
CD19+CD27+ memory B-cell pool depletion and therapy
effectiveness. [19–21].
There are some lines of evidence that the combination
of RTX and cytotoxic therapies could result in a more pro-
found reduction in B-cell number. The combination of MTX
and RTX forms part of the FCM-R regimen (fludarabine,
cyclophosphamide, MTX, and RTX), which is used in the
treatment of B-cell neoplasms with acceptable tolerability
[22]. It appears that RTX and MTX could target B cells
through different mechanisms. Therefore, we hypothesized
that the combination of RTX with MTX may be effective in
treatment of MS with high disease activity.
In this paper, we present the results of an observa-
tional pilot study of 28 MS patients who received a sin-
gle course of combined therapy with RTX-MTX together
with methylprednisolone (MP) and were followed clini-
cally and immunologically with a maximal follow-up of 48
months. This study still provides an important insight into
immunotherapy in MS.
2. Material and Methods
2.1. Patient Groups and Study Protocol. We assessed the
efficacy of a single course of combined immunosuppressive
therapy consisting of RTX and MTX together with methyl-
prednisolone (MP) in MS. 28 patients with clinically definite
MS (MacDonald 2005 criteria [23]) aged 18 to 55 who had
at least one relapse in the 6 months prior to enrolment were
recruited. All patients provided informed consent prior to
study enrolment, and the study was approved by the local
ethics committee.
The study group consisted of 8 patients resistant to
standard therapy (beta-interferons, glatiramer acetate) and
8 patients who were resistant to different therapeutic
approaches including bone marrow transplantation and 12
therapy näıve patients with very active MS. Disease modify-
ing agents were withdrawn 1 month prior to any treatment
in this study. The clinical details of the study participants are
summarised in Table 1.
The therapeutic protocol consisted of two infusions
14 days apart and was performed as an inpatient during
two separate hospital admissions to a specialised neuro-
logical department. On the first day, 1000mg methylpred-
nisolone (MP) IV was administered. On the second day,
1000mgMP IV, 1000mgRTX IV, and 20mgMTX IV were
given consecutively. Premedication with 1 g acetaminophen
(paracetamol) and 20mg diphenhydramine (piriton) IV was
given 30 minutes prior to RTX infusion. On the third day,
1000mgMP IVwas administered.The patients were readmit-
ted on day 14when 1000mgMP IV and 1000mgRTX IVwere
administered.
For the initial three weeks, we checked complete blood
counts and urinalysis every third day. Clinical and laboratory
data as well as MRI examination were performed at several
fixed time-points during the first year: 6 months, 9 months,
and 12 months. After the first year of followup, patients were
observed clinically at intervals of 6 months. At the date of
paper preparation, the minimum duration of followup was 12
months and maximum observation period was 48 months.
The primary clinical endpoint was the tolerability of
the combined regimen, and the primary imaging endpoint
was the reduction in number of gadolinium-enhancing MRI
lesions.
An aim of the study was to determine the changes in
clinical disease measures, in the dynamics of B-cell popula-
tions cerebrospinal fluid (CSF), and in peripheral blood (PB).
As there was no placebo arm, clinical examinations were
unblinded and performed for safety rather than efficacy.
2.2. Clinical and Magnetic Resonance Imaging Examinations.
Before treatment, all patients underwent an extended neuro-
logical examinationwith formalised clinical scales (EDSS and
MSFC) and anMRI. All patients were screened for viral hep-
atitis (B,C), HIV-1, and syphilis and had echocardiography
and a chest X-ray performed. Blood and CSF were sampled
1 day prior to treatment.
The safety of the combination of RTX and MTX was
determined by infusion-associated adverse events (AEs),
drug-related AE, and infection-associated AE according to
the National Cancer Institute (NCI) Common Toxicity Cri-
teria (CTC) version 3.0 grading system over the study period
[24, 25].
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Table 1: Summary of clinical data of patients under study.
Patient
no./sex/age,
yrs
Type of
MS
Time since
initial
symptoms,
yrs
Time since
diagnosis,
yrs
MS therapy in
previous 5 yrs EDSS at baseline
Relapses in
previous 2 yrs
MRI findings
(within 6 months before
treatment)
T2/T1/T1Gd
OCB
1/F/25 RR 3 1 None 3.0 3 34/22/5 +
2/F/21 RR 3 2 None 2.0 2 48/9/3 +
3/F/26 SP 4 3 INF𝛽-1b 250 𝜇g 6.0 4 35/11/3 +
4/M/23 RR 2 2 INF𝛽-1a 30𝜇g 3.0 3 24/8/2 +
5/F/25 RR 2 2 INF𝛽-1b 250𝜇g 4.0 3 53/18/3 +
6/M/38 PP 12 10 GAAuto-HSCT 6.0 4 38/20/0 +
7/F/42 RR 6 6 Auto-HSCT 2.0 1 38/15/5 −
8/M/28 SP 10 10 INF𝛽-1b 250 𝜇g 7.5 4 31/12/10 +
9/F/35 SP 12 10 Auto-HSCT 6.0 1 38/23/0 +
10/F/20 RR 2 2 INF𝛽-1b 250 𝜇g 4.0 2 133/34/7 +
11/M/25 RR 3 3 None 4.5 4 23/6/4 +
12/F/28 RR 4 3 INF𝛽-1b 250𝜇gMitoxantrone 5.0 4 24/7/8 +
13/M/50 RR 10 5 None 4.0 1 40/21/5 +
14/M/53 RR 1 0 GA 6.5 2 24/0/10 +
15/F/34 RR 6 4 GA 4.0 1 30/10/4 +
16/F/29 RR 4 2 None 6.0 3 27/8/4 +
17/M/29 RR 15 14 None 6.0 4 92/47/6 +
18/F/28 RR 3 2 INF𝛽-1b 250𝜇g 4.0 2 33/8/1 +
19/M/28 SP 4 2 None 6.0 3 24/8/9 +
20/M/30 SP 3 3 GA mitoxantrone 9.0 4 22/13/7 +
21/M/51 SP 12 10 INF𝛽-1b 250 𝜇g 6.0 1 32/20/0 +
22/F/54 SP 13 10 GA mitoxantrone 6.5 3 28/19/6 +
23/M/24 RR 1 1 None 3.0 3 130/40/2 +
24/F/44 SP 6 5 None 6.0 2 36/3/1 +
25/M/23 RR None 4.0 2 12/0/4 +
26/F/36 RR 4 4 None 6.0 3 4/1/4 +
27/F/40 RR 4 3 None 5.5 4 89/23/3 +
28/F/55 SP 3 3 Mitoxantrone 8.0 4 22/2/8 +
RR: relapsing-remitting; PP: primary progressive; SP: secondary progressive; INF𝛽: interferon beta; GA: glatiramer acetate; Auto-HSCT: autohematopoietic
stem cells transplantation; T2(PD): hyperintense lesions; T1: hypointense lesions; T1Gd: gadolinium-enhanced lesions; OCB: oligoclonal bands.
MRI examinations were performed with 1.5 TMRI appa-
ratus (Siemens AG, Germany). Imaging endpoints were the
change from baseline in the total number of gadolinium-
(Gd-enhancing) T1 lesions, the total number of new T2
lesions, and the number of lesions changing from T2 to T1.
MRI section thickness was 1mm, and lesions greater than
3mm in two dimensions were scored.
2.3. Flow Cytometry and Other Immunological Tests. Periph-
eral blood was taken on the day of lumbar puncture and
examined using flow cytometry for the expression of lympho-
cyte markers CD3, 4, 8, 16, 56, 19, 27, HLADR, and CD4/25.
Samples of CSF were taken by lumbar puncture. Aliquots of
5mL CSF were sent for flow cytometry studies.The cells were
spun down with careful centrifugation (1000 G), and 1mL of
cell pellet was taken for analysis. In all cases, samples were
analysed within 4 hours of lumbar puncture.
A 50mL aliquot of CSF was sent for immunological
studies including the detection of IgG oligoclonal bands by
isoelectric focusing and immunoblotting in paired CSF and
serum samples, according to established methods [26].
3. Results
3.1. Safety. AEs were systematically examined during the
study in all enrolled patients. An immediate infusion reaction
of a urticarial rash and weakness developed in 1 patient
and resolved spontaneously within 24 hours following the
first infusion. This did not recur at the time of the second
rituximab infusion (Table 2).
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Table 2: Adverse events in study population according to the
common toxicity criteria, version 3.0.
Events Patients
𝑛 (%)
Drug-related events affecting
Headache 5 (17.8%)
Nausea 3 (10.7%)
Fatigue 10 (35.7%)
Throat irritation 1 (3.5%)
Infusion-associated event—number of
patients (%)∗∗∗
First infusion at w 0 1 (3.5%)
Second infusion at w 2 0
Specific infection-associated
event—number of patients (%)
Nasopharyngitis 11 (39.2%)
Upper respiratory tract infection 2 (15.3%)
Urinary tract infection 1 (3.5%)
Sinusitis 1 (3.5%)
Common toxicity criteria
Grade 1 28 (100%)
Grade 2 24 (86%)
Grade 3 16 (57%)
Grade 4 13 (46%∗)
Grade 5 0
Serious adverse event∗ 0 (0%)
∗All cases presented with transient neutropenia (less than 500 cell/mL)
which resolved spontaneously by day 19.
∗∗Serious adverse events were defined as life threatening, resulting in
death, requiring prolonged inpatient hospitalization, resulting in a congenital
anomaly or malignant condition, or requiring surgical intervention to
prevent one of these outcomes.
∗∗Infusion-associated event included any adverse event occurring during or
within 24 hours after rituximab and mitoxantrone infusion in all patients.
A transient neutropenia of less than 1500 cells per
microlitre was found in 100% (28/28) of patients but
completely resolved in all patients by day 19 since the
first infusion. This represents an AE that is recognized as
grade 1–3 toxicity. In 46% (13/28) of patients, neutrophil
counts were less than 500 cells per microlitre—that is,
grade 4 toxicity. Detailed data on leukocyte and neutrophil
counts is presented in Figure 1. This neutropenia was not
complicated by infection or neutropenic fever, and spon-
taneous resolution was noted in all patients within 5–7
days. Malaise and fatigue were associated with neutrope-
nia in all patients. Other noninfectious AEs are presented
in Table 2.
Upper respiratory tract infections including the common
cold and nasopharyngitis were most frequent during the first
year of observation and were seen in 13 (46%) patients. In
all cases, infections weremild and resolved without antibiotic
therapy.
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Figure 1: Dynamic of mean values of white blood cells (WBC), neu-
trophils (Neutroph), and lymphocytes (Lymph) after first infusion of
rituximab with mitoxantrone and intravenous methylprednisolone.
𝑥-axis represents days after infusion.
3.2. Clinical and Imaging Data. There were no relapses
amongst patients receiving the combined therapy during the
period of observation (Figure 2).
We found that treatment was associated with a significant
decrease in the EDSS from 5.1 ± 1.7 to 3.5 ± 2.0 (𝑃 < 0.0001)
in those patients followed up for 24 months (Figure 3). In
89% of patients, a persistent decrease in the EDSS score was
seen, without any maintenance therapy. In 3/8 patients who
were previously treated with bone marrow transplantation, a
gradual increase of EDSS was seen (mean 0.5 point) by 6, 12,
and 18 months of observation.
The baselineMRI examination was performed during the
3 months prior to the start of treatment. 89.3% (25/28) of
patients had Gd-enhancing MRI lesions. The mean number
of Gd-enhancing lesions was 4.43 ± 2.90 (range 0–10). All
patients manifested new T2 lesions within the 3months prior
to therapy. The mean count of T2 lesions was 42 ± 31 (range
4–133), and the mean count of T1 lesions was 15 ± 12 (range
0–47).
After 12 months of followup, the mean number of T2
lesions was 42±32 (range 4–133) and T1 lesions 15±12 (range
0–47) (Figure 4). During the study followup, no patients
developed either Gd-enhancing or new T2 lesions.
There was a positive correlation between the number of
Gd-enhancing lesions prior to treatment and the decrease in
EDSS. Amore pronounced decrease in EDSS at 6months was
seen in those patients who hadmore Gd-enhancing lesions at
baseline (𝑟 = 0.42, 𝑃 = 0.025).
3.3. Immunology. We performed serial measurements of
CD3-CD19+ B-cell and CD3-CD19+CD27+ memory B-cell
subpopulations in peripheral blood and CSF. B-cell deple-
tion (>95% reduction from baseline) in peripheral blood
was confirmed in all patients at 6 months (Figure 5(a)).
At 9 months, B cells reappeared in the peripheral blood
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Patient
1/F/25
2/F/21
3/F/26
4/M/23
5/F/25
6/M/38
7/F/42
8/M/28
9/F/35
10/F/20
11/M/25
12/F/28
13/M/50
14/M/53
15/F/34
16/F/29
17/M/29
18/F/28
19/M/28
20/M/30
21/M/51
22/F/54
23/M/24
24/F/44
25/M/23
26/F/36
27/F/40
28/F/55
Months −24 −18 −12 −6 −3 0 6 12 18 24
RTX + MTX + MPNo./sex/age, y
Figure 2: Number of relapses and period of observation before and after treatment. Month 0: start of the treatment; 󳵳: relapse.
(mean 0.018 ± 0.014× 10 ∗ 9 cells per liter) and expanded
to 0.049 ± 0.080× 10 ∗ 9 cells per liter. In the majority of
the patients, complete restoration of the number of B cells
in peripheral blood occurred at 15 months after treatment.
However, the number of CD27+ memory B cells was still
significantly decreased compared to baseline (Figure 6(a)).
The number of B cells in peripheral blood fell over 150
times, while in the CSF the decrease was less pronounced and
resulted in an approximate 5-fold reduction (Figure 5(b)). In
the CSF, B cells dropped from 0.024 ± 0.028× 10 ∗ 6 cells per
liter to 0.005 ± 0.008× 10 ∗ 6 cells per liter (𝑃 = 0.0034). By
12 months, B cells in the CSF had reached their initial levels
of 0.022 ± 0.023× 10 ∗ 6 cells per liter (𝑃 = 0.687).
We found a more rapid reconstitution of B cells in the
CSF than in the peripheral blood. By 9 months, B cells in the
peripheral blood were still significantly lower (𝑃 = 0.001)
than prior to therapy, whilst in the CSF, the number of B
cells had returned to the levels observed prior to treatment
(Figure 5).
Oligoclonal IgG bands in CSF samples were tested before
therapy and at 12 months after therapy and were found in
all patients. The frequency and intensity of oligoclonal IgG
bands were unchanged at 12 months.
4. Discussion
The rationale for our proposed treatment strategy is the gen-
eral finding that “biologic” agents are more effective if used
in combination with immunosuppressive or antiproliferative
drugs. In the treatment of rheumatoid arthritis or system
lupus erythematosis, RTX monotherapy is significantly less
potent than RTXused in combinationwith another cytostatic
drug such as cyclophosphamide or methotrexate [8].
We treated 28 patients with a single therapeutic course of
RTX-MTX-MP in combination and followed these patients
for more than 1 year. All patients had very highMS activity at
the time of enrolment in this study.
The treatment regimen was generally well tolerated and
any immediate infusion reactions observed were mild. The
unexpected finding in all patients treated with the combined
therapy of RTX-MTX-MP was the high frequency of early
neutropenia noticed by days 7–12. In over 40% of patients,
the absolute neutrophil number was less than 500 cells per
microliter. Neutropenia was characterized by fast recovery,
taking less than 7 days, and the neutropaenia did not require
treatment with colony-stimulating factors and/or antibiotics.
There were no infection-related AEs associated with neu-
tropaenia.
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Figure 3: Dynamic of EDSS (mean) for a period observation of 30
months. Significant decrease in the EDSS score from 5.1±1.7 before
treatment to 3.5 ± 2.0 (𝑃 < 0.0001) at 12 months after treatment
initiation in 28 patients and a decrease in the EDSS score from 5.1 ±
1.7 before treatment to 3.5 ± 2.0 (𝑃 < 0.0001) at 24 months after
treatment in 15 patients. ∗∗𝑃 < 0.001; ∗∗∗𝑃 < 0.0001.
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Figure 4: Dynamic of Gd-enhanced lesions after therapy with
rituximab with mitoxantrone and intravenous methylprednisolone
during observation period. Along the period of observation after
combined therapy, there were neither Gd-enhancing MRI lesions
nor new T2 lesions in any of the study patients.
Neutropenia is a recognised rare adverse effect of RTX
therapy and is classified into early onset and late onset
forms. The latter is more clinically relevant and typically
occurs 2 to 4 months following RTX administration [27].
According to the data onhematological complications of RTX
monotherapy, late onset RTX-induced neutropenia is seen in
6% of patients treated with a single course of the drug [28].
Cytotoxic drugs such as cyclophosphamide, which have been
administered together with RTX in the treatment of systemic
lupus erythematosis and other rheumatological diseases, have
not been found to increase the frequency of either early or late
onset RTX-induced neutropenia [20].
Published data suggests that late onset neutropenia could
be related to an excess of T-lymphocyte populations which
express and secrete large amounts of Fas and Fas Lig-
and (FasL) leading to the apoptosis of mature neutrophils
and the production of antineutrophil autoantibodies [29–
31]. Another possible cause of neutropenia in RTX-treated
patients is associated with the very high levels of BAFF,
a strong stimulator of B-cell recovery, that can be seen in
patients after B-cell depletion. These high levels could, in
theory, promote B-cell lymphopoiesis in the bone marrow at
the expense of normal granulopoiesis [32].
The dose of MTX typically recommended for monother-
apy for MS (12mg/m2) induces transient neutropenia in
approximately one-third (27%) of patients [33]. When
administered as a monotherapy, MTX-induced neutropenia
usually peaks at 7–14 days and resolves by 21 days following
treatment initiation.
Our patients were followed clinically throughout the
observation period which varied from 12 to 48 months.
We confirmed suppression of MS activity and remission in
89% of patients that was sustained during followup. The
absence of Gd-enhancing and new T2 lesions on repeated
MRI suggests a profound decrease of inflammatory activity
in these previously highly active MS patients. In most of
the patients, clinical course of MS after single course of
the combined therapy did not require any maintenance
therapy during observation at the moment of the last data
collection.
We noted B-cell depletion in peripheral blood which
persisted for up to 15 months. In general, our data on the
dynamics of B-cell counts is compatible with the results of
the HERMES study. In the HERMES study, it was shown
that RTX monotherapy induced a rapid depletion of CD19+
peripheral B lymphocytes from 2 weeks after treatment until
24 weeks. By week 48, CD19+ cells had returned to 30.7%
of baseline values [13]. The number of CD27+ memory B
cells in peripheral blood was still significantly decreased
compared to baseline. We have also shown that in the CSF
B cells reappeared at 9 months, and there was a preservation
of oligoclonal IgG bands at 1 year that probably reflects
propagation of intrathecal B cells.
The high frequency of neutropenia and long-term
decrease in CD27+ memory B cells in our patients may
reflect a biological synergism of the proposed combination
of RTX andMTX with MP. Synergistic drug combinations of
few relatively “strong” medications can potentially decrease
the cumulative dose of any one medication and thus reduce
some treatment associated risks. Such a combination could
possibly be reserved as an escalation opportunity for patients
with particularly active disease and poor prognostic fac-
tors [34], or as a preferable alternative to other induction
approaches such as alemtuzumab [35], cladribine [4], high-
dose cyclophosphamide (RevImmune) [36], and bone mar-
row transplantation.
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Figure 5: Dynamic of CD19+ cells in peripheral blood (a) and CSF (b) after treatment. ∗𝑃 < 0.05; ∗∗𝑃 < 0.001; ∗∗∗𝑃 < 0.0001.
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Figure 6: Dynamic of CD19+CD27+ memory B cells in peripheral blood (a) and CSF (b) after treatment. ∗∗∗𝑃 < 0.0001; ∗∗𝑃 = 0.0059.
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